- Clinical Trials
Two Austin-based companies involved in medial research say they expect to raise millions of dollars with stock offerings this week.
Genprex has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules.
World reknowned medical and clinical experts to guide Genprex’ novel gene therapy clinical development programs in cancer and diabetes, including its two upcoming clinical trials in lung cancer
Joins Global Movement to Raise Awareness and Reduce the Burden of Cancer Worldwide
Mr. Redman provides his reaction to a recent article in ONCOLOGY® and discusses how Genprex is harnessing breakthroughs in lung cancer treatment.
Major milestones achieved in advancing gene therapies for lung cancer and diabetes
Company to provide update on upcoming clinical trials for the treatment of non-small cell lung cancer and an overview of its diabetes gene therapy
Presentation to Highlight Company’s Recent Advancements on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer
Presentation to Highlight the Company’s Recent Progress on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer
Company passes final release tests of scaled-up clinical grade production to supply drug product for upcoming Acclaim-1 and Acclaim-2 clinical trials in lung cancer